share_log

Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC

Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC

政府，官員為阿斯利康的新冠肺炎注射辯護：CNBC
Benzinga Real-time News ·  2021/04/09 00:14
  • The British government and health experts in the country have come forward to defend the COVID-19 vaccine developed by AstraZeneca plc’s (NASDAQ: AZN) and Oxford after a possible link to blood clots have raised concerns, reports CNBC.
  • One Twitter user commented Thursday that officials appear to have gone into “damage limitation” mode.
  • Yesterday, European Medicines Agency concluded that unusual blood clots should be listed as a “very rare side effect” of the AZN COVID-19 shot. The EMA has not placed any age restrictions on recipients, however.
  • The U.K.’s health and vaccine regulators issued a change of guidance over who should receive the shot, and now they recommend that anyone under 30 years of age should go for an alternative vaccine amid the concerns.
  • Following a safety review of the AstraZeneca vaccine, both the U.K. and European medicines regulators stressed that the shot’s benefits still outweighed the risks.
  • Meanwhile, U.K. Prime Minister Boris Johnson, who has received a first shot of the vaccine himself, said that “the best thing people should do is look at what the MHRA said. “Their advice to people is to keep going out there, get your jab, get your second jab,” he added.
  • “It does sound like a sensible decision based on the evidence we have so far of a probable causal link between the AZ vaccine and these very rare thrombotic side effects that have been noted,” Andrew Freedman, reader in infectious diseases at Cardiff University School of Medicine, told CNBC. However, he noted that vaccine hesitancy was now “clearly a concern.”
  • EMA’s Executive Director Emer Cooke noted that researchers were still trying to determine what has been causing a small number of severe but rare clots, including cerebral venous sinus thrombosis.
  • To date, four European countries have stopped using the AstraZeneca vaccine altogether, including Denmark and the Netherlands. In contrast, others, including Germany, France, and Spain, have put age restrictions on the shot.
  • Price Action: AZN shares are trading 2.3% higher at $49.54 on the last check Thursday.
  • 英國政府和該國的衞生專家挺身而出，為英國政府研發的新冠肺炎疫苗辯護。阿斯利康(AstraZeneca Plc)據CNBC報道，納斯達克(Nasdaq：AZN)和牛津大學(Oxford)在可能與血液凝塊有關後，已經提出了擔憂。
  • 一位推特用户週四評論説，官員們似乎已經進入了“損害限制”模式。
  • 昨天，歐洲藥品管理局得出結論，不尋常的血栓應該被列為注射氮磷新冠肺炎的“非常罕見的副作用”。然而，EMA沒有對接受者施加任何年齡限制。
  • 英國衞生和疫苗監管機構就誰應該接種疫苗發佈了新的指導意見，現在他們建議30歲以下的人都應該選擇替代疫苗，因為人們對此感到擔憂。在這種情況下，英國的衞生和疫苗監管機構發佈了一項新的指導意見，建議30歲以下的人接種替代疫苗。
  • 在對阿斯利康(AstraZeneca)疫苗進行安全性審查後，英國和歐洲藥品監管機構都強調，注射的好處仍然大於風險。
  • 與此同時，英國首相鮑里斯·約翰遜(Boris Johnson)表示，“人們應該做的最好的事情就是看看MHRA説了什麼。”約翰遜本人也已經接種了第一針疫苗。他補充説：“他們給人們的建議是繼續走出去，打你的針，打你的第二針。”
  • 卡迪夫大學醫學院傳染病讀者安德魯·弗裏德曼告訴CNBC：“根據我們迄今掌握的證據，AZ疫苗和這些已經注意到的非常罕見的血栓副作用之間可能存在因果聯繫，這聽起來確實是一個明智的決定。”然而，他指出，疫苗的猶豫不決現在“顯然是一個令人擔憂的問題”。
  • EMA的執行主任Emer Cooke指出，研究人員仍在努力確定是什麼導致了少量嚴重但罕見的血栓，包括腦靜脈竇血栓形成。
  • 到目前為止，包括丹麥和荷蘭在內的四個歐洲國家已經完全停止使用阿斯利康疫苗。相比之下，包括德國、法國和西班牙在內的其他國家則對拍攝施加了年齡限制。
  • 價格行動：在週四的最後一次檢查中，AZN股價上漲2.3%，至49.54美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論